BioPharma Credit

Bioeureka is a pioneering company that employs advanced AI-powered image recognition technology to revolutionize microbiology. Its core business involves the development of an AI-driven platform designed for swift pathogen identification. This platform analyzes, catalogs, and interprets images of samples from microscopes, using a user-friendly smartphone or computer interface. The result is immediate and accurate identification of bacteria, viruses, and fungi, significantly enhancing efficiency in microbiological testing.

Tarsus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for ophthalmic conditions, with a pipeline that includes first-in-class candidates aimed at Demodex blepharitis and other eye diseases. Its lead program, TP-03, targets blepharitis caused by Demodex mites and is advancing through Phase IIb/III trials, alongside efforts to address meibomian gland disease. The company is also developing TP-04 for rosacea and TP-05 for Lyme prophylaxis and community malaria reduction, indicating a broader dermatology and infectious-disease focus. Tarsus pursues development across opportunities with unmet medical need, aiming to bring novel therapeutics to patients with limited treatment options. The company was founded in 2016 and is headquartered in Irvine, California.

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company headquartered in Raleigh, North Carolina, dedicated to addressing the needs of patients with chronic pain and opioid dependence. Founded in 1997, the company focuses on the development and commercialization of innovative pharmaceutical products, leveraging its proprietary BioErodible MucoAdhesive (BEMA) drug-delivery technology. This technology allows for the creation of small erodible polymer films designed for effective application to the buccal mucosa. BioDelivery Sciences offers a range of products, including BELBUCA, a buprenorphine buccal film for chronic pain management, and BUNAVAIL, a buprenorphine and naloxone buccal film aimed at treating opioid dependence. Additionally, it provides ONSOLIS, a fentanyl buccal soluble film for managing breakthrough pain in cancer patients, and Symproic, which treats opioid-induced constipation in adults with chronic pain. The company's focus on novel drug delivery methods enables it to address important unmet medical needs in pain management and addiction medicine.

NovoCure Limited is an oncology company focused on the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) therapy for solid tumors. The company markets Optune and the NovoTTF-100L system as monotherapy treatments for adult glioblastoma and is pursuing a pipeline of TTFields products for other cancers, including brain metastases, non-small cell lung cancer, pancreatic, ovarian, liver cancers, and mesothelioma. Its products are marketed in the European Union, Japan, and other international markets. NovoCure maintains research collaborations to advance TTFields, including a clinical trial collaboration with MSD to evaluate TTFields with KEYTRUDA and an alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology for preclinical and clinical development projects. Founded in 2000, the company is based in Saint Helier, Jersey.